Containing Proteins Or Derivatives Thereof (e.g., Gelatin, Etc.) Patents (Class 424/460)
  • Patent number: 9132098
    Abstract: A nanoparticulate composition for the targeted therapeutic treatment of tumors. The stable self assembled nanocomposition according to the invention comprises (i) a carrier and targeting system comprising an optionally modified polyanion, and optionally a polycation, which may also be modified; at least one targeting agent which is linked to either the polycation/modified polycation or the polyanion/modified polyanion, or both, or to the surface of the nanoparticle; (ii) an active compound selected from the group of doxorubicin and its pharmaceutically acceptable salts, especially hydrochloride; and optionally (iii) at least one complexing agent, a metal ion, a stabilizer/formulating agent, or a PEGylating agent. The present invention furthermore relates to a process for the preparation of the above-mentioned composition, the therapeutic uses thereof, and pharmaceutical compositions containing the nanocomposition according to the invention.
    Type: Grant
    Filed: December 19, 2013
    Date of Patent: September 15, 2015
    Assignee: BBS Nanotechnology Ltd.
    Inventors: János Borbély, Zsuzsanna Csikós, Gáborné Koncz, Ildikó Schriffertne Denyicska
  • Patent number: 9095568
    Abstract: Polyelectrolyte nanoparticle compositions for biomedical applications are provided comprising at least two carrier domains comprising multivalent ionic domains and an agent exhibiting biological activity when contained within the nanoparticle or on the nanoparticle surface. The multivalent ionic domains may be contained in two separate molecules or in separate but linked domains of a single molecule. The nanoparticle optionally can further comprise an exposed targeting ligand and/or protective surface. The nanoparticle can be contacted to cells or administered directly to an animal for biomedical applications including therapeutics and immune response. The nanoparticle may alternatively be comprised of a carrier material capable of delivering various medically important antigens as vaccine.
    Type: Grant
    Filed: September 26, 2008
    Date of Patent: August 4, 2015
    Inventors: Mark Berninger, Puthupparampil Scaria
  • Patent number: 8980822
    Abstract: Embodiments of the invention provide swallowable devices, preparations and methods for delivering drugs and other therapeutic agents within the GI tract. Many embodiments provide a swallowable device for delivering the agents. Particular embodiments provide a swallowable device such as a capsule for delivering drugs into the intestinal wall or other GI lumen. Embodiments also provide various drug preparations that are configured to be contained within the capsule, advanced from the capsule into the intestinal wall and degrade to release the drug into the bloodstream to produce a therapeutic effect. The preparation can be operably coupled to delivery means having a first configuration where the preparation is contained in the capsule and a second configuration where the preparation is advanced out of the capsule into the intestinal wall. Embodiments of the invention are particularly useful for the delivery of drugs which are poorly absorbed, tolerated and/or degraded within the GI tract.
    Type: Grant
    Filed: June 29, 2012
    Date of Patent: March 17, 2015
    Assignee: Rani Therapeutics, LLC
    Inventor: Mir Imran
  • Patent number: 8980320
    Abstract: A film coating agent for a solid formulation includes a water-soluble cellulose derivative, swelling clay, a cationic surfactant, and a fatty acid, wherein mass ratio of the swelling clay to the water-soluble cellulose derivative is 2:8 to 8:2, and content of the cationic surfactant is not less than 0.5 equivalents and not more than 3.0 equivalents relative to a cation exchange equivalent of the swelling clay.
    Type: Grant
    Filed: November 30, 2010
    Date of Patent: March 17, 2015
    Assignee: Toray Industries, Inc.
    Inventors: Ryoji Yoshii, Yuki Hayashi, Yuki Fujisaki
  • Patent number: 8974820
    Abstract: The invention provides an apparatus for producing soft gel capsules having encapsulated therein microparticles, nanoparticles and fluids, said apparatus comprising: (a) two spreader boxes; (b) two casting drums; (c) a pair of rotary dies; (d) a liquid fill system (medicine pump system); (e) a wedge for heating gelatine ribbons and feeding said fill; and (f) one or more microgranule or nanogranule feeders located on each side of the rotary dies, said feeders being synchronized to rotate at the same tangential speed as the rotary dies.
    Type: Grant
    Filed: July 18, 2011
    Date of Patent: March 10, 2015
    Assignee: Procaps SAS
    Inventors: Carlos Salazar Altamar, Gustavo Anaya, Braulio Teran, Newman Aguas Navarro, Willmer Herrera
  • Patent number: 8969293
    Abstract: Embodiments of the invention provide swallowable devices, preparations and methods for delivering drugs and other therapeutic agents within the GI tract. Many embodiments provide a swallowable device for delivering the agents. Particular embodiments provide a swallowable device such as a capsule for delivering drugs into the intestinal wall or other GI lumen. Embodiments also provide various drug preparations that are configured to be contained within the capsule, advanced from the capsule into the intestinal wall and degrade to release the drug into the bloodstream to produce a therapeutic effect. The preparation can be operably coupled to delivery means having a first configuration where the preparation is contained in the capsule and a second configuration where the preparation is advanced out of the capsule into the intestinal wall. Embodiments of the invention are particularly useful for the delivery of drugs which are poorly absorbed, tolerated and/or degraded within the GI tract.
    Type: Grant
    Filed: June 29, 2012
    Date of Patent: March 3, 2015
    Assignee: Rani Therapeutics, LLC
    Inventor: Mir Imran
  • Patent number: 8895062
    Abstract: The invention provides surface-layer protein coated microspheres for delivery of a therapeutic agent to the intestine. These surface-layer protein coated microspheres generally include a core encapsulated by a microsphere which is coated by surface layer protein. The core includes a therapeutic agent, such as a defensin. The invention also includes methods of making and using the surface-layer protein coated microspheres of the invention for administering therapeutic agents to a subject in need thereof. The invention also includes pharmaceutical dosage units that include the surface-layer protein coated microspheres of the invention. The invention further includes various labeled defensins for use in the study of the properties and actions of defensins, and further includes the use of defensins, particularly HD5? in the treatment of inflammatory conditions of the bowel, such as Crohn's disease.
    Type: Grant
    Filed: January 24, 2007
    Date of Patent: November 25, 2014
    Assignee: University of Maryland, Baltimore
    Inventors: Erik P. H. De Leeuw, Wuyuan Lu
  • Patent number: 8822423
    Abstract: We have disclosed affinity peptides toward infliximab. More specifically we have disclosed an affinity biomatrix where the affinity peptide is covalently attached to a biocompatible, biodegradable polymer. The affinity biomatrix is useful in preparing controlled release devices for infliximab.
    Type: Grant
    Filed: May 17, 2012
    Date of Patent: September 2, 2014
    Assignee: Janssen Biotech, Inc.
    Inventors: Daphne Ann Salick Ryan, John Kehoe, John Wheeler, Chunlin Yang, Abla Creasey
  • Patent number: 8808736
    Abstract: A multiparticulate composition is formed from a plurality of individual cores including a hydrophobic phase containing peppermint oil dispersed in a microcrystalline cellulose-based gel and a hydrophilic phase containing a hydrogel. An enteric coating is over the individual cores. The multiparticulate composition can be used to treat gastrointestinal disorders.
    Type: Grant
    Filed: September 23, 2013
    Date of Patent: August 19, 2014
    Assignee: Zx Pharma, LLC
    Inventors: Syed Shah, Daniel Hassan, Fred Hassan
  • Patent number: 8809271
    Abstract: Embodiments of the invention provide swallowable devices, preparations and methods for delivering drugs and other therapeutic agents within the GI tract. Many embodiments provide a swallowable device for delivering the agents. Particular embodiments provide a swallowable device such as a capsule for delivering drugs into the intestinal wall or other GI lumen. Embodiments also provide various drug preparations that are configured to be contained within the capsule, advanced from the capsule into the intestinal wall and degrade to release the drug into the bloodstream to produce a therapeutic effect. The preparation can be operably coupled to delivery means having a first configuration where the preparation is contained in the capsule and a second configuration where the preparation is advanced out of the capsule into the intestinal wall. Embodiments of the invention are particularly useful for the delivery of drugs which are poorly absorbed, tolerated and/or degraded within the GI tract.
    Type: Grant
    Filed: June 29, 2012
    Date of Patent: August 19, 2014
    Assignee: Rani Therapeutics, LLC
    Inventor: Mir Imran
  • Patent number: 8765174
    Abstract: A matrix formulation for a soft chewable capsule is provided which includes a gel-forming composition, a plasticizer, a polymer modifier, and water. The polymer modifier may be a carboxylic acid or other organic compound that alters the physical and/or chemical properties of the capsule formulation. A chewable soft capsule is also provided, having enhanced organo-leptic and processing properties. An active material may be delivered to a user using this dosage form. A method of forming the chewable soft capsule is also provided.
    Type: Grant
    Filed: December 15, 2011
    Date of Patent: July 1, 2014
    Assignee: Banner Pharmacaps Inc.
    Inventors: EmadEldin M. Hassan, Warren W. Kindt, Roger E. Gordon
  • Patent number: 8759284
    Abstract: Embodiments of the invention provide swallowable devices, preparations and methods for delivering drugs and other therapeutic agents within the GI tract. Many embodiments provide a swallowable device for delivering the agents. Particular embodiments provide a swallowable device such as a capsule for delivering drugs into the intestinal wall or other GI lumen. Embodiments also provide various drug preparations that are configured to be contained within the capsule, advanced from the capsule into the intestinal wall and degrade within the wall to release the drug to produce a therapeutic effect. The preparation can be coupled to an actuator having a first configuration where the preparation is contained in the capsule and a second configuration where the preparation is advanced out of the capsule into the intestinal wall. Embodiments of the invention are particularly useful for the delivery of drugs which are poorly absorbed, tolerated and/or degraded within the GI tract.
    Type: Grant
    Filed: December 23, 2010
    Date of Patent: June 24, 2014
    Assignee: Rani Therapeutics, LLC
    Inventor: Mir Imran
  • Patent number: 8545891
    Abstract: The disclosure relates to sunscreen compositions having a synergistic combination of titanium dioxide filtering agents that provide a high sun protection factor (SPF). Compositions according to the disclosure have high SPF values without requiring high overall amounts of titanium dioxide filtering agents. Also, the sunscreen compositions are less opaque and white than traditional sunscreens making them aesthetically appealing to consumers. Finally, the disclosure relates to methods of using the described compositions for protecting keratinous substances such as skin and hair from UV radiation.
    Type: Grant
    Filed: December 28, 2012
    Date of Patent: October 1, 2013
    Assignee: L'OREAL
    Inventors: Susan Halpern, Jean-Thierry Simonnet
  • Publication number: 20130122086
    Abstract: Enteric compositions comprising one or more tight junction agonists and/or one or more tight junction antagonists are provided. Compositions of the invention may comprise a delayed-release coating disposed over a tight junction agonist and/or tight junction antagonist layer which may be disposed over an inert core. Delayed-release coatings may be substantially stable in gastric fluid and substantially unstable in intestinal fluid, thus providing for substantial release of the tight junction agonist and/or antagonist from the composition in the duodenum or jejunum of the small intestine.
    Type: Application
    Filed: April 18, 2012
    Publication date: May 16, 2013
    Applicant: Alba Therapeutics Corporation
    Inventors: Blake Paterson, Mark J. Ginski
  • Patent number: 8383577
    Abstract: Methods, formulations and kits are described that allow for the controlled release of octreotide, e.g., octreotide acetate, in a subject.
    Type: Grant
    Filed: April 29, 2011
    Date of Patent: February 26, 2013
    Assignee: Endo Pharmaceuticals Solutions, Inc.
    Inventors: Petr Kuzma, Stefanie Decker, Harry Quandt
  • Patent number: 8314154
    Abstract: A topical anti-aging skin care formulation comprising an effective amount of a benzoquinone, such as CoQ10, plus a synergistic pair of stabilizers and a synergistic pair of whiteners. The stabilizers are octyl salicylate and octyl methoxycinnamate. The whiteners are titanium dioxide and zinc oxide. When proper amounts of these ingredients are used in an aqueous based emulsion formulation, the product will be initially white, and will remain white for an extended period of time.
    Type: Grant
    Filed: September 22, 2008
    Date of Patent: November 20, 2012
    Inventor: Louise Holyfield
  • Patent number: 8236353
    Abstract: The present invention relates to pharmaceutical formulations for the release of an active principle (AP) over a sustained period of time. The invention relates to a liquid formulation comprising at least one active principle (AP) and an aqueous suspension based on colloidal particles of a polymer (PO), wherein said formulation satisfies the following four conditions: (a) the PO is a polyamino acid comprising glutamic residues, wherein some glutamic residues each carry a pendant cationic group (CG), said CG being identical or different from one another, and other glutamic residues each carry a pendent hydrophobic group (GH), said GH being identical or different from one another, (b) the pHf value of the pH of said formulation is between 3.0 and 6.5; (c) at the pHf value, the PO forms a colloidal solution which associates spontaneously and noncovalently with the AP; (d) 1 ml of said formulation precipitates during mixing with a volume of 1 ml of a test buffer solution Tp.
    Type: Grant
    Filed: May 5, 2008
    Date of Patent: August 7, 2012
    Assignee: Flamel Technologies
    Inventors: Frédéric Checot, Cecile Bonnet-Gonnet, You-Ping Chan, Olivier Breyne, Remi Meyrueix
  • Patent number: 8197850
    Abstract: The invention concerns an oral galenic form for prolonged release of anti-hyperglycaemic (metformin) active principles. Said medicine enables to obtain an efficient therapeutic protection over 24 hours by overcoming the problems of bypass of the absorption window and the massive localised release of active principles. Therefor, said medicine comprises several thousand anti-hyperglycaemic (metformin) microcapsules each consisting of a core comprising at least an anti-hyperglycaemic agent and of a coating film applied on the core and enabling the prolonged release in vivo of the anti-hyperglycaemic agent. Said microcapsules have a grain size distribution ranging between 50 and 100 microns. The reproducibility of the transit kinetics and hence of bioavailability are very high. There results for the patient a lesser risk of hyperglycaemic or hypoglycaemic. The invention also concerns the preparation of said medicine and the use of a plurality of said microcapsules for making an anti-hyperglycaemic medicine.
    Type: Grant
    Filed: November 19, 2001
    Date of Patent: June 12, 2012
    Assignee: Flamel Technologies
    Inventors: Catherine Castan, Remi Meyrueix, Gerard Soula
  • Patent number: 8084045
    Abstract: The present invention relates to novel pharmaceutical formulations based on stable, fluid aqueous colloidal suspensions for the prolonged release of active principle(s), particularly protein active principle(s), and to the applications, especially therapeutic applications, of these formulations. The object of the invention is to propose a fluid pharmaceutical formulation for the prolonged release of active principle(s) that makes it possible, after parenteral injection, to increase significantly the in vivo release time of a therapeutic protein while at the same time reducing the plasma concentration peak of the active protein, said formulation furthermore being stable on storage and also being biocompatible, biodegradable, non-toxic and non-immunogenic and having a good local tolerance.
    Type: Grant
    Filed: November 19, 2004
    Date of Patent: December 27, 2011
    Assignee: Flamel Technologies
    Inventors: Gauthier Pouliquen, Olivier Soula, Rémi Meyrueix, Florence Nicolas
  • Patent number: 8071537
    Abstract: Described herein are implantable devices, formulations and methods of making implantable devices for the release of a polypeptide from an implantable device, and methods of use thereof.
    Type: Grant
    Filed: June 24, 2009
    Date of Patent: December 6, 2011
    Assignee: Endo Pharmaceuticals Solutions Inc.
    Inventors: Petr Kuzma, Stefanie Decker, Harry Quandt
  • Patent number: 8062663
    Abstract: Methods and compositions for enhancing transdermal delivery of a bioactive agent. The method contains the step of applying to a skin tissue an effective amount of a composition comprising: (a) a drug vehicle; (b) a bioactive agent encapsulated within the drug vehicle; (c) a plurality of proteolytic enzyme molecules conjugated onto the surface of the drug vehicle; and (d) a pharmaceutically acceptable carrier, for a period of time effective to deliver the bioactive agent across the skin tissue at a desired dosage.
    Type: Grant
    Filed: May 14, 2009
    Date of Patent: November 22, 2011
    Assignee: National Health Research Instittues
    Inventors: Yu-Jing Wang, Yu-Chao Wang, Yi-Ting Wu, Lin-Ai Tai, Leu-Wei Lo, Chung-Shi Yang
  • Patent number: 8034382
    Abstract: The disclosure provides a method to form sustained release drug-containing microparticles with a biodegradable polymer. The method involves forming a polymer-drug-organic solvent phase, and dispersing the polymer-drug-organic solvent phase in an aqueous suspension of an inorganic gel, which may be hydroxyapatite. The hydroxyapatite appears to coat the polymer-drug-solvent droplets to prevent them coalescing. The solvent then evaporates with stirring of the dispersion, at which time the droplets solidify to drug-containing microparticles. The inorganic gel allows suitably small microparticles to form without use of an organic emulsifier.
    Type: Grant
    Filed: July 31, 2008
    Date of Patent: October 11, 2011
    Assignee: The Board of Trustees of the University of Arkansas
    Inventor: Cherng-Ju Kim
  • Patent number: 7959939
    Abstract: A laminate comprising a transparent collagen I type sheet and a human corneal endothelial cell culture layer provided on the sheet. An endothelial cell culture layer laminate usable in transplantation is provided.
    Type: Grant
    Filed: February 17, 2005
    Date of Patent: June 14, 2011
    Inventors: Satoru Yamagami, Tatsuya Mimura, Shiro Amano, Keisuke Tanaka, Shunji Hattori, Shinkichi Irie, Yasuhiro Osakabe
  • Patent number: 7960335
    Abstract: Methods, formulations and kits are described that allow for the controlled release of octreotide, e.g., octreotide acetate, in a subject.
    Type: Grant
    Filed: June 24, 2009
    Date of Patent: June 14, 2011
    Assignee: Endo Pharmaceuticals Solutions Inc.
    Inventors: Petr Kuzma, Stefanie Decker, Harry Quandt
  • Patent number: 7785650
    Abstract: Water soluble, gelatin-free dip coatings for pharmaceutical solid dosage forms such as tablets comprising HPMC and xanthan gum, carrageenan, and mixtures thereof, or HPMC and castor oil or maltodextrin.
    Type: Grant
    Filed: June 27, 2007
    Date of Patent: August 31, 2010
    Assignee: McNeil-PPC, Inc.
    Inventors: Cynthia Gulian, Walter G. Gowan, Jr., Kishor B. Parekh, Joseph M. Morris, Thomas J. Markley, Dennis C. Wieand, Gerard P. McNally, Christopher Szymczak
  • Patent number: 7767708
    Abstract: An improved weight and growth stimulant for domesticated animals such as cattle, pigs and sheep is comprised of an anabolic agent that is subcutaneously administered in the form of a dual release implant formulation. Increased gains are particularly improved when zeranol is administered in an immediate-release and controlled-release formulation which allows for a one-time dosage injection.
    Type: Grant
    Filed: November 1, 1999
    Date of Patent: August 3, 2010
    Assignee: Schering-Plough Animal Health Corp.
    Inventors: Shih Chung, Thomas J. Kennedy, Peter James Knight, Daniel S. Robins, Zezhi Jesse Shao
  • Patent number: 7332160
    Abstract: The present invention relates to medical devices that are to be implanted or inserted into the body of a patient for the purpose of removing undesired body tissues. In one embodiment of the invention the medical device comprises a body tissue removal agent for removing undesired body tissue simultaneously with or prior to treatment of body tissue that is in proximity to the undesired body tissue with a biologically active material. Such biologically active material may facilitate regeneration of the body tissue that was removed or may prevent the recurrence of the undesired body tissue.
    Type: Grant
    Filed: July 12, 2002
    Date of Patent: February 19, 2008
    Assignee: Boston Scientific Scimed, Inc.
    Inventors: Toby Freyman, Wendy Naimark
  • Patent number: 7153840
    Abstract: This invention is directed towards a ready-to-use aqueous composition of fludarabine phosphate. In one embodiment, the invention is directed to an aqueous fludarabine phosphate composition which comprises fludarabine phosphate, a base, and water. The concentration of fludarabine phosphate in the composition may be between about 0.5 mg/mL and about 50 mg/mL. The pH of the composition may be between about 5.5 and about 7.1.
    Type: Grant
    Filed: May 23, 2003
    Date of Patent: December 26, 2006
    Assignee: Sicor, Inc.
    Inventors: Dorla Mirejovsky, Peter Lindsay Macdonald
  • Patent number: 7148207
    Abstract: This invention relates to a quick-release tablet formulation with >99.19% pure fludara (high-purity fludara) as an active ingredient in a defined composition of residual contaminants.
    Type: Grant
    Filed: December 20, 2002
    Date of Patent: December 12, 2006
    Assignee: Schering Aktiengesellschaft
    Inventors: Wolfgang Heil, Ulf Tistam, Ralph Lipp, Johannes-Wilhelm Tack
  • Patent number: 7045146
    Abstract: Process for encapsulation of an uncharged crystalline solid particle include treating the crystalline solid particle material with amphiphilic substances and subsequently coating the material with a layer of charged polyelectrolyte or coating the material with a multilayer comprising alternating layers of oppositely charged polyelectrolytes.
    Type: Grant
    Filed: January 12, 2001
    Date of Patent: May 16, 2006
    Assignee: Max-Planck-Gesellschaft zur Forderung der Wissenschaften e.V.
    Inventors: Frank Caruso, Dieter Trau, Helmuth Möhwald, Reinhard Renneberg
  • Patent number: 6994873
    Abstract: This invention refers to: multiparticulate formulations of Lithium salts for oral administration constituted by either modified release granules or mixtures of modified and conventional release granules, suitable for once-a-day administration also at high strengths of Lithium salts, and to the preparation process of said formulations.
    Type: Grant
    Filed: February 4, 2002
    Date of Patent: February 7, 2006
    Assignee: Valpharma S.A.
    Inventors: Roberto Valducci, Tiziano Alighieri, Serozh Avanessian
  • Patent number: 6926938
    Abstract: The present invention provides a process for preparing hardshell gelatin capsule reducing the static electricity and enhancing the lubrication of film having good film distribution in capsule comprising the steps of: i) preparing an emulsion containing 0.4˜0.8 part by weight of diacetylated monoglycerides, 0.05˜0.1 part by weight of sodium lauryl sulfate, and 0.005˜0.01 part by weight of colloidal silicon dioxide; ii) adding the emulsion to gelatin solution containing 100 part by weight of gelatin; iii) mixing and homogenizing the resulting solution; iv) adjusting viscosity of mixture; v) allowing the obtained product to stand; and vi) forming a hardshell gelatin capsule therefrom.
    Type: Grant
    Filed: July 28, 2003
    Date of Patent: August 9, 2005
    Assignee: Suheung Capsule Co., Ltd.
    Inventor: Joo Hwan Yang
  • Patent number: 6926906
    Abstract: The present invention relates to a pharmaceutical formulation for oral administration through a soft gelatin capsule drug delivery device, wherein the pharmaceutical formulation has Pseudoephedrine HCl as the active pharmaceutical ingredient. The active pharmaceutical ingredient is embedded into an oily matrix, also the formulation comprises viscosity imparting agents, a surfactant; a suspending agent; and a suspension medium. The viscosity-imparting agents are partially hydrogenated vegetable oil and colloidal silicon dioxide, the surfactant is lecithin, the suspending agent is yellow beeswax, and the suspension medium is soybean oil. In one preferred embodiment, the formulation consists essentially of about 60 mg by weight of Pseudoephedrine HCl, about 15-25 mg by weight of partially hydrogenated vegetable oil, about 10-20 mg by weight of yellow beeswax, about 2-8 mg by weight of lecithin, about 2-8 mg by weight of silicon dioxide; and about 150-250 mg by weight of soybean oil.
    Type: Grant
    Filed: March 13, 2002
    Date of Patent: August 9, 2005
    Assignee: M./S. Strides, Inc.
    Inventors: Ramachandran Radhakrishnan, Nehru Babu Gaddipati
  • Patent number: 6884432
    Abstract: Microspheres for controlled release of a bioactive agent are disclosed, and in particular, blend, cross-linkable poly(propylene fumarate) for immobilization and controlled drug delivery. The microsphere includes poly(propylene fumarate), a polymeric material other than poly(propylene fumarate) (e.g., poly(lactic-co-glycolic acid)), and a bioactive agent. The bioactive agent is selected depending on the physiological effect desired. For example, in bone regeneration applications, the bioactive agent may be selected from osteoinductive agents, peptides, growth hormones, osteoconductive agents, cytokines and mixtures thereof. The bioactive agent is dispersed in the microsphere, the microsphere has a diameter in the range of 1 to 300 micrometers, the poly(propylene fumarate) and poly(lactic-co-glycolic acid) are distributed in the microsphere, and the microsphere releases the bioactive agent in a sustained manner after an initial burst release.
    Type: Grant
    Filed: April 25, 2003
    Date of Patent: April 26, 2005
    Assignee: Mayo Foundation for Medical Education and Research
    Inventors: Michael J. Yaszemski, Bradford L. Currier, Lichun Lu, Xun Zhu, Esmaiel Jabbari, Diederik H. R. Kempen
  • Patent number: 6849271
    Abstract: The present invention relates to microspheres, processes for the manufacture of said microspheres, pharmaceutical compositions comprising said microspheres, and sustained release methods of administering an effective pharmaceutical amount of a bioactive compound to a subject. The microspheres of the present invention comprise a water insoluble organic matrix comprising an interior region, throughout which are homogeneously dispersed a plurality of microcapsules consisting essentially of a core of bioactive compound coated with material containing charged organic groups and a surface region substantially free of said bioactive compound.
    Type: Grant
    Filed: October 18, 2002
    Date of Patent: February 1, 2005
    Assignee: Verion, Inc.
    Inventors: Farid Vaghefi, Martin F. Savitzky
  • Patent number: 6821530
    Abstract: The invention relates to methods of treating mixtures containing polymeric materials, e.g., collagen, to form a polymer that intercalates into the polymeric material. The treatment provides greater tensile strength to the mixture, among other advantages. The polymer is formed of a monomeric unit having at least one catechol group that is oxidized to a quinone upon polymerization.
    Type: Grant
    Filed: May 19, 2003
    Date of Patent: November 23, 2004
    Assignee: Shriners Hospitals for Children
    Inventors: Thomas J. Koob, Daniel J. Hernandez
  • Patent number: 6814971
    Abstract: The invention relates to adjuvants that contain a lecithin, an oil and an amphiphilic surfactant and that are capable of forming a stable oil-in-water emulsion vaccine so as to minimize local reactions to the vaccine in the injected animal.
    Type: Grant
    Filed: March 13, 2003
    Date of Patent: November 9, 2004
    Assignee: Pfizer Inc.
    Inventors: David S. Roberts, Leroy A. Swearingin, Don A. Dearwester
  • Patent number: 6809182
    Abstract: The present invention provides compositions of matter comprising 29p protein having bound thereto an agent whose delivery into a eukaryotic cell is desired. The present invention also provides a monoclonal antibody which specifically binds to 29p protein. The present invention further provides methods for delivering an agent into a eukaryotic cell, and methods for causing a eukaryotic cell to secrete a desired protein in the form of a fusion protein. The present invention further provides 29p protein-containing pharmaceutical compositions. The present invention still further provides nucleic acid molecules which hybridize to at least a portion of a nucleic acid molecule encoding 29p protein. Finally, the present invention provides methods for detecting the presence of, and quantitatively determining the amount of, a 29p protein-encoding nucleic acid molecule in a sample.
    Type: Grant
    Filed: January 25, 2001
    Date of Patent: October 26, 2004
    Assignee: The Trustees of Columbia University in the City of New York
    Inventors: Saul J. Silverstein, Paula W. Annuziato, Anne A. Gershon, Octavian Lungu
  • Patent number: 6733754
    Abstract: The invention relates to adjuvants that contain a lecithin, an oil and an amphiphilic surfactant and that are capable of forming a stable oil-in-water emulsion vaccine so as to minimize local reactions to the vaccine in the injected animal.
    Type: Grant
    Filed: March 13, 2003
    Date of Patent: May 11, 2004
    Assignees: Pfizer, Inc., Pfizer Products, Inc.
    Inventors: David S. Roberts, Leroy A. Swearingin, Don A. Dearwester
  • Patent number: 6706284
    Abstract: The invention relates to an oral pharmaceutical composition which has excellent drug release-controlling ability in the mouth even 5 to 10 minutes after its administration and also has excellent drug releasing ability in the digestive tract without using capsules. It also relates to an oral pharmaceutical composition which comprises one or more drugs having a bitter taste, one or more solid proteins, and one or more pharmaceutically acceptable polymer bases, wherein the proteins are present in the polymer bases preferably as particles.
    Type: Grant
    Filed: March 14, 2002
    Date of Patent: March 16, 2004
    Assignee: Yamanouchi Pharmaceutical Co., Ltd.
    Inventors: Masahiro Yanagisawa, Takao Mizumoto
  • Patent number: 6699501
    Abstract: The invention relates to a method for producing capsules provided with a polyelectrolyte covering, and to the capsules obtained using this method.
    Type: Grant
    Filed: March 7, 2001
    Date of Patent: March 2, 2004
    Assignee: Max-Planck-Gesellschaft zur Forderung der Wissenschaften. e.V.
    Inventors: Björn Neu, Hans Bäumler, Edwin Donath, Sergio Moya, Gleb Sukhobukov, Helmuth Möhwald, Frank Caruso
  • Patent number: 6696086
    Abstract: The present invention relates to a novel solid pharmaceutical formulation containing lovastatin and simvastatin, respectively, with a particle size D(0.9) between 15 and 100 &mgr;m and a specific particle surface area between 1 and 4 m2/g, and to the process for its preparation. The present invention also relates to the method for production of lovastatin and simvastatin with the size of crystals which are suitable for the preparation of the pharmaceutical formulation of the present invention. The novel solid pharmaceutical formulation is useful for treating hypercholesterolemia and hyperlipidemia.
    Type: Grant
    Filed: September 8, 2000
    Date of Patent: February 24, 2004
    Assignee: Lek Pharmaceuticals d.d.
    Inventors: Zlatko Pflaum, Mateja Salobir, Zdenka Jerala, Aleksander Resman
  • Patent number: 6685962
    Abstract: Pharmaceutical gastroretentive drug delivery systems for the controlled release of an active agent in the gastrointestinal tract are disclosed, which comprise: (a) a single- or multi-layered matrix comprising a polymer that does not retain in the stomach more than a conventional dosage form selected from (1) degradable polymers that may be hydrophilic polymers not instantly soluble in gastric fluids, enteric polymers substantially insoluble at pH less than 5.5 and/or hydrophobic polymers and mixtures thereof; (2) non-degradable polymers; and any mixtures of (1) and (2); (b) a continuous or non-continuous membrane comprising at least one polymer having a substantial mechanical strength; and (c) a drug; wherein the matrix when affixed or attached to the membrane prevents evacuation from the stomach of the delivery system for a period of time of from about 3 to about 24 hours.
    Type: Grant
    Filed: May 29, 2002
    Date of Patent: February 3, 2004
    Assignee: Yissum Research Development Company Of The Hebrew University Of Jerusalem
    Inventors: Michael Friedman, Eytan Klausner, Eran Lavy, Amnon Hoffman
  • Patent number: 6673814
    Abstract: The present invention relates to methods useful for the treatment of neoplastic diseases, tumor cells, and the treatment of cancer delivering compounds of the formula The invention provides various methods of delivering such compounds, combinations of treatments, and altering such compounds to enhance their effectiveness.
    Type: Grant
    Filed: January 25, 2002
    Date of Patent: January 6, 2004
    Assignee: Emory University
    Inventors: Harish C. Joshi, Keqiang Ye, Judith Kapp, Jaren Landen, David Archer, Cheryl Armstrong, Fuqiang Liu
  • Patent number: 6645525
    Abstract: Compositions for sustained delivery of a biomolecule including an anionic polymer and a cationic polymer which ironically interact with each other and, optionally, with the biomolecule. Methods for making the compositions, including the step of combining the negatively charged polymer with the positively charged polymer to form an ionic complex are also provided. The biomolecule may be complexed with one of the polymers before it is complexed with the oppositely charged polymer. The complex is exposed to conditions that cause the formation of precipitated microcarriers, such as a change in pH or the addition of a complexing molecule. The compositions are preferably formulated into microcarriers.
    Type: Grant
    Filed: May 6, 2002
    Date of Patent: November 11, 2003
    Assignee: Sedum Laboratories, Inc.
    Inventor: James E. Woiszwillo
  • Patent number: 6627223
    Abstract: A pharmaceutical dosage form such as a capsule capable of delivering therapeutic agents into the body in a time-controlled or position-controlled pulsatile release fashion, is composed of a multitude of multicoated particulates (beads, pellets, granules, etc.) made of one or more populations of beads. Each of these beads except an immediate release bead has at least two coated membrane barriers. One of the membrane barriers is composed of an enteric polymer while the second membrane barrier is composed of a mixture of water insoluble polymer and an enteric polymer. The composition and the thickness of the polymeric membrane barriers determine the lag time and duration of drug release from each of the bead populations. Optionally, an organic acid containing intermediate membrane may be applied for further modifying the lag time and/or the duration of drug release.
    Type: Grant
    Filed: February 7, 2001
    Date of Patent: September 30, 2003
    Assignee: Eurand Pharmaceuticals Ltd.
    Inventors: Phillip Percel, Krishna S. Vishnupad, Gopi M. Venkatesh
  • Publication number: 20030147946
    Abstract: Aqueous dispersions of crystalline polymers based on hydrophobic monomers, preferably on a mixture of hydrophobic and hydrophilic monomers which contains a crosslinking monomer, particularly side chain crystalline (SCC) polymers. The dispersions are useful for providing coatings on substrates, particularly on seeds (whose dormancy is thus extended) and on fibrous substrates, particularly human hair (which thus becomes heat-settable).
    Type: Application
    Filed: December 17, 2002
    Publication date: August 7, 2003
    Inventors: Ray F. Stewart, Natarajan Balachander, Steven P. Bitler, Loc Phan, Valentine Y. Yoon
  • Patent number: 6596543
    Abstract: The present invention relates generally to the field of prothrombin time reagents for determining dysfunction in the coagulation system and more specifically to reagents made from native thromboplastin or purified or recombinant tissue factor and phospholipids from a natural or synthetic source. The present invention relates to methods to make a diagnostic reagent that includes a membrane-bound protein incorporated into a liposome and having additional empty liposomes (liposomes without membrane-bound protein incorporated therein) added to the solution.
    Type: Grant
    Filed: March 22, 2001
    Date of Patent: July 22, 2003
    Assignee: Dade Behring Inc.
    Inventors: Jianfang Wang, Kevin Bruce Johnson, Liliana Maria Tejidor, Hema Doobay
  • Patent number: 6592895
    Abstract: Precursor polyhydric alcohol esters where acyl moieties originate from aliphatic homopolymer or copolymer polyesters and contain free hydroxyl at their terminal ends, are reacted to provide 2-carboxy ethenyl groups. The resulting products can be used in formation of hydrogels for drug delivery or can be reacted to attach aminoxyl radical or drug molecule residue or other biologically active agent for delivery of these, for example, from vascular stents.
    Type: Grant
    Filed: July 15, 2002
    Date of Patent: July 15, 2003
    Assignee: Cornell Research Foundation, Inc.
    Inventors: Meidong Lang, Chih-Chang Chu
  • Patent number: RE42096
    Abstract: A multiple pulsed dose drug delivery system for pharmaceutically active amphetamine salts, comprising an immediate-release component and an enteric delayed-release component wherein (1) the enteric release coating has a defined minimum thickness and/or (2) there is a protective layer between the pharmaceutically active amphetamine salt and the enteric release coating and/or (3) there is a protective layer over the enteric release coating. The product can be composed of either one of a number of beads in a dosage form, including either capsule, tablet, or sachet method for administering the beads.
    Type: Grant
    Filed: March 24, 2005
    Date of Patent: February 1, 2011
    Inventors: Beth A. Burnside, Xiaodi Guo, Kimberly Fiske, Richard A. Couch, Rong-Kun Chang, Donald J. Treacy, Charlotte M. McGuiness, Edward M. Rudnic